New hope for Hard-to-Treat cervical cancer? drug trial targets HER2

NCT ID NCT07051486

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing a drug called SHR-A1811 in 60 women with HER2-expressing cervical cancer that has spread or returned after standard treatments. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A1811 (an antibody-drug conjugate targeting HER2)
What this could lead to: If successful, this could offer a new treatment option for people with HER2-positive cervical cancer that has not responded to standard therapies.
What could go wrong: This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors in many patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Recurrence Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT OR METASTATIC CERVICAL CANCER

Contacts and locations

Locations

Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350011, China
Shandong University Qilu Hospital
RECRUITING

Jinan, Shandong, 250063, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.